In cancer labs across Europe, a modest vitamin usually linked to hair supplements is suddenly stealing the spotlight from blockbuster drugs.
Researchers are starting to suspect that vitamin B7, better known as biotin, may be one of the quiet levers that help tumours survive when their favourite fuel is cut off.
How a humble vitamin gives tumours a metabolic escape route
A new study from the University of Lausanne highlights an unexpected role for vitamin B7 in the way cancer cells handle their energy needs.
Cancer cells often show a strong “addiction” to glutamine, an amino acid that provides both carbon and nitrogen. They use it to power energy production and to build DNA and other vital molecules. Many experimental drugs try to starve tumours by blocking this glutamine supply.
Yet some tumours keep growing even when glutamine is scarce. The Swiss team has now shown that vitamin B7 can help explain how they manage this remarkable feat.
Vitamin B7 acts like a metabolic licence, allowing cancer cells to bypass their dependence on glutamine and switch to a backup fuel.
The key player is an enzyme called pyruvate carboxylase. Enzymes are proteins that speed up chemical reactions inside cells. Pyruvate carboxylase converts pyruvate, a breakdown product of glucose, into oxaloacetate.
Oxaloacetate then feeds the Krebs cycle, the series of reactions in mitochondria that generates much of the cell’s energy. When glutamine runs low, some cancer cells push more pyruvate into this route to keep the Krebs cycle running. This refilling process has a name: anaplerosis.
Vitamin B7 is crucial here. Biotin must bind directly to pyruvate carboxylase for the enzyme to work properly. Without this attachment, the reaction stalls, the Krebs cycle is no longer replenished, and the cell cannot compensate for the lack of glutamine. Its growth slows dramatically.
Why some anti-glutamine therapies fail
Using detailed metabolic tracing and large-scale genetic screening, the Lausanne researchers showed that biotin and pyruvate carboxylase sit at the centre of this bypass mechanism.
➡️ In Australia, an 8 cm larva found in a patient’s brain
➡️ Could A Titanic Chinese Engineering Project Really Slow The Earth’s Rotation? What NASA Says
➡️ Russia Prepares To “Release The Kraken” In The Baltic Sea To Secure A Vital Export Lifeline
➡️ Valentine’s Day: This Is The Ideal Hair Tool For A Dream Blowout
➡️ New anti-obesity drugs: stopping injections causes much faster weight regain than expected
➡️ Meet “stained glass hair”, the chic way to soften grey roots without hiding them
➡️ France called in by the Caribbean’s third-largest island for a €144 million water lifeline
The findings help explain why some therapies that only target glutamine metabolism have shown disappointing effects in trials. If a tumour has an efficient biotin–pyruvate carboxylase system, it can simply reroute fuel from glucose instead.
Blocking glutamine alone may be like closing one door while leaving a side entrance wide open.
Future strategies may need to hit both the glutamine pathway and this biotin‑dependent backup route at the same time, at least in tumours that rely on it.
When genetics turn a strength into a weakness: the FBXW7 link
The story does not stop with nutrients. The same study points to a close connection between vitamin B7 and a gene called FBXW7, a known tumour suppressor.
Under normal conditions, FBXW7 keeps a tight lid on a powerful growth-promoting protein named c‑MYC. By helping to clear c‑MYC from the cell, FBXW7 prevents excessive cell division.
When FBXW7 is mutated, this control fails. c‑MYC builds up and rewires the activity of many metabolic genes. One striking effect is a reduction in the production of pyruvate carboxylase.
With less pyruvate carboxylase, cancer cells lose much of their ability to use pyruvate as an alternative fuel during glutamine shortage. They slip back into strong dependence on glutamine to keep dividing.
The same genetic mutation that drives cancer growth can also strip away its metabolic backup plan, creating a hidden vulnerability.
This shows that tumour resistance does not just depend on what nutrients are available in the tumour’s surroundings. It also depends on each tumour’s specific genetic context. Certain mutations directly reshape what fuels the tumour can or cannot live without.
Metabolic flexibility: a defining trait of cancer cells
Vitamin B7 highlights a broader theme in cancer biology: metabolic flexibility. This term describes the ability of cells to shift energy sources based on what is on offer.
When glutamine levels fall, some tumours avoid crisis by turning up their use of pyruvate via the biotin‑dependent pyruvate carboxylase route. Others may tap into fatty acids or different amino acids.
This flexibility helps explain why single‑target metabolic drugs often hit a wall. Blocking one route just encourages cancer cells to lean on another.
- Glutamine-focused drugs may fail if pyruvate carboxylase is active.
- Glucose-targeting drugs may be dodged through greater use of glutamine or fats.
- Genetic mutations decide which backup routes are actually available.
Designing future therapies will likely mean combining drugs that hit several pathways and tailoring them to each tumour’s metabolic and genetic profile.
Could vitamin B7 itself become a therapeutic target?
Biotin is generally seen as a harmless micronutrient. It is widely present in food and supplements and plays roles in normal metabolism, including in healthy cells.
The new data do not suggest that patients should avoid biotin or change their diet. The concentrations used and the way cells handle vitamin B7 in a tumour microenvironment differ from everyday nutrition.
Where researchers see an opening is in understanding which tumours rely strongly on biotin‑dependent enzymes. In those cancers, drugs that interfere with biotin use or with specific biotin‑requiring enzymes such as pyruvate carboxylase could make glutamine‑targeting therapies more effective.
Biotin is shifting from background micronutrient to a potential handle for precision oncology.
Such approaches come with real challenges. Biotin is needed by many tissues, so systemic blockade could bring side effects, from nerve problems to skin issues. A key question will be whether drugs can be designed to act mainly on cancer cells, for example by exploiting differences in enzyme levels or nutrient transporters.
What patients and clinicians might want to know
For people living with cancer, these findings are not a cue to buy or stop taking biotin supplements. The research is based on cellular models and intricate metabolic mapping, not on clinical trials of vitamin intake.
Where this work matters is in the long‑term design of treatment combinations. Oncologists may one day order tests that do not just look for classical mutations but also profile enzymes such as pyruvate carboxylase and markers of biotin use. This could help sort tumours into categories such as:
| Tumour profile | Metabolic feature | Potential vulnerability |
|---|---|---|
| High pyruvate carboxylase, intact FBXW7 | Strong biotin‑dependent backup when glutamine is low | May respond better to dual glutamine + pyruvate carboxylase targeting |
| Low pyruvate carboxylase, mutated FBXW7 | Heightened glutamine dependence | Could be especially sensitive to glutamine‑blocking therapies |
| Mixed metabolic profile | Multiple fuel options | Likely needs broader multi‑pathway combinations |
Key terms that often confuse readers
Two concepts regularly appear in this research and are worth clarifying.
Anaplerosis refers to reactions that refill the Krebs cycle with new carbon molecules so that it can keep turning. Without anaplerosis, the cycle eventually runs out of raw material and energy output drops.
Tumour suppressor genes, such as FBXW7, act as brakes on cell division or survival. When they are damaged, cells can divide more freely and often change the way they manage nutrients. This can both fuel cancer and create weak points that targeted drugs might hit.
As researchers continue to map these intertwined pathways, vitamin B7 is likely to feature more often in cancer discussions, not as a lifestyle fad, but as a small molecule sitting at a surprisingly strategic crossroads of tumour metabolism and resistance.
Originally posted 2026-03-07 10:49:00.